
    
      The trial will include Norwegian adult males and females with symptomatic erosive
      inflammatory hand osteoarthritis.

      Participants will be randomized 1:1 to either:

        1. Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg
           the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if
           higher doses are not tolerated.

        2. Placebo (control group).

      Both arms will receive folic acid 1mg daily.

      The treatment duration for both groups is 52 weeks.
    
  